Thermo Fisher Scientific Inc. has opened its Doe & Ingalls Northeast cGMP chemical distribution facility to meet demand for compliance, production chemical storage, and supply chain services for the biopharmaceutical, life science, and advanced technology markets.
Located in Peabody, Mass., the 56,000 ft2, state-of-the-art facility is designed to protect raw material integrity, control the flow of goods, and deliver supply chain services. The facility is cGMP-compliant to assure products and processes are in strict compliance with regulatory agencies and meet and/or exceed standards for temperature control, audit log/documentation, and product handling/sampling. The facility’s features include the storage and warehousing of chemical and raw materials; a dip tube exchange and temperature-controlled 2-8°C cold storage; and ISO Class 8 and Class 100 cleanrooms provide sampling services for sourcing and quality control testing of production chemical materials.
“A secure, robust supply chain is crucial for manufacturers to remain competitive, reduce total cost of ownership, and mitigate risk of supply interruption,” says Jeff Jochims, president, research and safety markets, Thermo Fisher Scientific. “Our new Doe & Ingalls facility offers customers the ability to ramp up or expand their production capabilities quickly and cost-efficiently. By leveraging our scale and depth of capabilities in production materials supply chain, our customers can focus their internal resources on what they do best — developing new pharmaceuticals and technologies.”
“We welcome and celebrate this expansion,” says Massachusetts Governor Deval Patrick. “This facility underscores Thermo Fisher’s commitment to the leading life sciences supercluster in the world.”
“We congratulate Thermo Fisher on the opening of the Doe & Ingalls site,” says Robert K. Coughlin, president and chief executive officer of MassBio, a life sciences trade organization. “This site will be an excellent resource for our members, many of whom are challenged to operate as a GMP-compliant operation when it’s time to scale up to pilot manufacturing. This facility will provide critical services to get them up and running, shortening the time it takes to get new products to market and to the patients who need them.”
Release Date: May 8, 2014
Source: The Associated Press
